IMUGENE CHART. TA only, page-25621

First 25621 Last

Share
Profile

Follow
Thaliat

4,933 Posts.

836

11/10/23

21:57

Post #: 70297406
Share

Originally posted by Habibul bashar: ↑

Dear Habib

The impact of the last capital raising and Share Purchase Plan has left us baffled as to why our share price has been so severely sold off, and I’m sure you must ask yourself the same questions. Some softness in share price is expected after a raise, particularly with options attaching, but this time the impact has surprised us all. The move from the ASX 200 to the ASX 300 has also not helped.

With few exceptions, biotech companies on the ASX have been under pressure for nearly two years and unfortunately Imugene has felt the brunt of the market’s shunning of the sector, which has occurred both within Australia and on a global scale.

The recent feedback around the share price seems to focus on why we raised the money when we already had what appeared to be a deep war chest. The Board took the view that the scale of the azer-cel acquisition demanded a conservative approach to capital management, and therefore felt the most appropriate long-term strategy was to secure additional funding as we endure this tough economic climate.

Our balance sheet is now one of the strongest in the industry with ~$180 million in the bank, we are in good shape with a diversified technology portfolio, five company FDA INDs (the global gold standard for running human clinical trials) and another with City of Hope, and five clinical trials recruiting across the US and Australia. Coming up we have the onCARlytics study that will soon enrol patients, another investigator sponsored trial in combination with onCARlytics at City of Hope, and azer-cel’s Phase 1b expansion will start enrolling patients with the FDA having cleared the batch 1.2 dose. This is all supported by a highly qualified senior management team with very deep expertise in cell therapy, CAR T in solid tumours and in blood cancers. There are few ASX biotechs with such strength and depth.

With that said, it is difficult to understand the negative sentiment reflected in the low share price.

We want to assure you that your investment in Imugene and support of the Company is important to us both, the Board and management.

We are fully aware of the responsibility this brings to us and the management team. We are all deeply committed to achieving a return to a more favourable share price.

We would welcome any thoughts or suggestions from you and will endeavour to respond with a short turnaround.

Thanks and regards,

Paul Hopper and Leslie Chong

Expand

Yeah cheers for sharing, the only part that bothers me about this email is the ones posted before were so rude!

I wonder if the response from PH hanged dependent on the volume you hold? if that's the case it yet another attribute of PH I'm certainly not a fan of!

But once again thanks for your transparency!

IMU Price at posting: 5.0¢ Sentiment: Hold Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

CC9

Is a lithium revival on the cards in 2025? Chariot Corporation say yes!

BM8

Battery Age Minerals finds critical technology isotope Germanium-76 at Bleiberg

WIN

Out to WIN: The 'primed' gold play with sights set on WA production

TLX

Telix clocks +150% year-on-year returns as radiopharma acquisition well received

FMG

Fortescue is going to buy Red Hawk Mining. Why, and who are they?

First 25621 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change 0.001(1.32%)		Mkt cap ! $283.3M

Open	High	Low	Value	Volume
3.9¢	3.9¢	3.8¢	$158.5K	4.074M

Buyers (Bids)

No.	Vol.	Price($)
28	2777708	3.8¢

Sellers (Offers)

Price($)	Vol.	No.
3.9¢	2705269	19

View Market Depth

No.	Vol.	Price($)
28	2777708	0.038
70	8672361	0.037
63	10487246	0.036
51	7509166	0.035
10	749029	0.034

Price($)	Vol.	No.
0.039	2705269	19
0.040	1240728	10
0.041	1511493	11
0.042	2804803	17
0.043	2429611	12

Last trade - 12.29pm 28/01/2025 (20 minute delay)

IMU (ASX) Chart

IMUGENE CHART. TA only, page-25621

Is a lithium revival on the cards in 2025? Chariot Corporation say yes!

Battery Age Minerals finds critical technology isotope Germanium-76 at Bleiberg

Out to WIN: The 'primed' gold play with sights set on WA production

Telix clocks +150% year-on-year returns as radiopharma acquisition well received

Fortescue is going to buy Red Hawk Mining. Why, and who are they?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

IMUGENE CHART. TA only, page-25621

Top Stories

Is a lithium revival on the cards in 2025? Chariot Corporation say yes!

Battery Age Minerals finds critical technology isotope Germanium-76 at Bleiberg

Out to WIN: The 'primed' gold play with sights set on WA production

Telix clocks +150% year-on-year returns as radiopharma acquisition well received

Fortescue is going to buy Red Hawk Mining. Why, and who are they?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News